{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T17:15:00Z","timestamp":1787850900890,"version":"build-2784847793"},"reference-count":27,"publisher":"Wiley","issue":"1","license":[{"start":{"date-parts":[[2025,1,22]],"date-time":"2025-01-22T00:00:00Z","timestamp":1737504000000},"content-version":"vor","delay-in-days":21,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Health Science Reports"],"published-print":{"date-parts":[[2025,1]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background and Aims<\/jats:title>\n                    <jats:p>Non\u2010Alcoholic Steatohepatitis (NASH), a severe form of Non\u2010Alcoholic Fatty Liver Disease (NAFLD), is characterized by inflammation and fibrosis in the liver, often progressing to cirrhosis and hepatocellular carcinoma. Despite its rising prevalence and significant disease burden, effective pharmacological treatments have been limited to lifestyle modifications and surgical interventions. Recently, resmetirom, a thyroid hormone receptor\u2010\u03b2 agonist, received FDA approval for treating NASH, offering new hope to patients. This review explores the current understanding of NASH and the role of resmetirom as a breakthrough therapeutic option.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This study is a comprehensive literature review analyzing peer\u2010reviewed articles, clinical trial data, and public health reports. No original analyses were conducted, and no statistical software was utilized in this review.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Resmetirom demonstrated efficacy in resolving NASH without fibrosis progression and improving fibrosis scores in patients with biopsy\u2010confirmed NASH. In a randomized Phase 3 trial, significant histological improvements were observed in 25.9% and 29.9% of patients receiving 80 and 100\u2009mg doses, respectively, compared to 9.7% in the placebo group. Similar trends were noted in fibrosis improvement, with 24.2% and 25.9% of patients showing \u2265\u20091 stage improvement compared to 14.2% in the placebo group. Adverse effects, including nausea and diarrhea, were reported more frequently in the treatment groups, but the rates of serious adverse events were comparable across groups.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>The approval of resmetirom marks a significant advancement in the treatment of NASH, addressing the limitations of lifestyle\u2010based interventions. As the obesity epidemic drives the increasing prevalence of NASH, resmetirom provides a promising therapeutic option, paving the way for improved patient outcomes and future research.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/hsr2.70394","type":"journal-article","created":{"date-parts":[[2025,1,22]],"date-time":"2025-01-22T07:45:20Z","timestamp":1737531920000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":12,"title":["A New Hope for the Patients of Non\u2010Alcoholic Steatohepatitis: FDA Gives Green Signal for Resmetirom Use"],"prefix":"10.1002","volume":"8","author":[{"ORCID":"https:\/\/orcid.org\/0009-0003-9913-0509","authenticated-orcid":false,"given":"Abdul Haseeb","family":"Hasan","sequence":"first","affiliation":[{"name":"Department of Medicine King Edward Medical University Lahore Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0001-9623-042X","authenticated-orcid":false,"given":"Muhammad Ali","family":"Abid","sequence":"additional","affiliation":[{"name":"Department of Medicine King Edward Medical University Lahore Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Muhammad Hafi","family":"Abid","sequence":"additional","affiliation":[{"name":"Department of Medicine Faisalabad Medical University Faisalabad Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laiba","family":"Suhail","sequence":"additional","affiliation":[{"name":"Department of Medicine King Edward Medical University Lahore Pakistan"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6650-6982","authenticated-orcid":false,"given":"Abubakar","family":"Nazir","sequence":"additional","affiliation":[{"name":"Department of Medicine King Edward Medical University Lahore Pakistan"},{"name":"Oli Health Magazine Organization Kigali Rwanda"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,1,22]]},"reference":[{"key":"e_1_2_8_2_1","unstructured":"\u201cNonalcoholic Fatty Liver Disease (NAFLD) & NASH\u2014NIDDK \u201d National Institute of Diabetes and Digestive and Kidney Diseases accessed March 19 2024 https:\/\/www.niddk.nih.gov\/health-information\/liver-disease\/nafld-nash."},{"key":"e_1_2_8_3_1","doi-asserted-by":"publisher","DOI":"10.2147\/DDDT.S315724"},{"key":"e_1_2_8_4_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0104-9"},{"key":"e_1_2_8_5_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.2298"},{"key":"e_1_2_8_6_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrgastro.2017.109"},{"key":"e_1_2_8_7_1","doi-asserted-by":"publisher","DOI":"10.1002\/hep.28431"},{"key":"e_1_2_8_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.gastha.2022.06.016"},{"key":"e_1_2_8_9_1","unstructured":"\u201cFDA Approves First Treatment for Patients With Liver Scarring Due to Fatty Liver Disease \u201d Commissioner of the FDA 2024 https:\/\/www.fda.gov\/news-events\/press-announcements\/fda-approves-first-treatment-patients-liver-scarring-due-fatty-liver-disease."},{"key":"e_1_2_8_10_1","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2020-320622"},{"key":"e_1_2_8_11_1","doi-asserted-by":"publisher","DOI":"10.3748\/wjg.v20.i7.1724"},{"key":"e_1_2_8_12_1","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2019.00202"},{"key":"e_1_2_8_13_1","doi-asserted-by":"publisher","DOI":"10.31083\/j.rcm2203082"},{"key":"e_1_2_8_14_1","doi-asserted-by":"publisher","DOI":"10.1007\/s00395-008-0733-0"},{"key":"e_1_2_8_15_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0136822"},{"key":"e_1_2_8_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijdevneu.2009.03.005"},{"key":"e_1_2_8_17_1","doi-asserted-by":"publisher","DOI":"10.1080\/14779072.2018.1497974"},{"key":"e_1_2_8_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2020.110785"},{"issue":"1","key":"e_1_2_8_19_1","first-page":"40","article-title":"Drugs for Non\u2010Alcoholic Steatohepatitis (NASH): Quest for the Holy Grail","volume":"9","author":"Sharma M.","year":"2021","journal-title":"Journal of Clinical and Translational Hepatology"},{"key":"e_1_2_8_20_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0907929"},{"key":"e_1_2_8_21_1","unstructured":"\u201cMadrigal Pharmaceuticals Announces FDA Approval of RezdiffraTM(Resmetirom) for the Treatment of Patients With Noncirrhotic Nonalcoholic Steatohepatitis (NASH) With Moderate to Advanced Liver Fibrosis \u201d Madrigal Pharmaceuticals accessed March 19 2024 https:\/\/ir.madrigalpharma.com\/news-releases\/news-release-details\/madrigal-pharmaceuticals-announces-fda-approval-rezdiffratm."},{"key":"e_1_2_8_22_1","unstructured":"\u201cREZDIFFRA (Resmetirom) Tablets for Oral Use Initial U.S. Approval: 2024 \u201d U.S. Food and Drug Administration 2024 https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2024\/217785s000lbl.pdf."},{"key":"e_1_2_8_23_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2309000"},{"key":"e_1_2_8_24_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eprac.2024.04.016"},{"key":"e_1_2_8_25_1","doi-asserted-by":"publisher","DOI":"10.1093\/ije\/dyz273"},{"key":"e_1_2_8_26_1","doi-asserted-by":"publisher","DOI":"10.2337\/ds017-0025"},{"key":"e_1_2_8_27_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11940-015-0383-0"},{"key":"e_1_2_8_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ecl.2020.02.003"}],"container-title":["Health Science Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/hsr2.70394","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,26]],"date-time":"2025-11-26T12:31:34Z","timestamp":1764160294000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1002\/hsr2.70394"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":27,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2025,1]]}},"alternative-id":["10.1002\/hsr2.70394"],"URL":"https:\/\/doi.org\/10.1002\/hsr2.70394","archive":["Portico"],"relation":{},"ISSN":["2398-8835","2398-8835"],"issn-type":[{"value":"2398-8835","type":"print"},{"value":"2398-8835","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"2024-03-31","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-01-06","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-01-22","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e70394"}}